한글목차

세계 우르소데옥시콜산 API 시장 전망은 약국 및 건강 제품 시장에서의 기회로 인해 유망합니다. 세계 우르소데옥시콜산 API 시장은 2025-2031년 11.2%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 간 질환의 유병률 증가, 담석 치료를 위한 우르소데옥시콜산의 채택률 증가, 의료비 지출 증가입니다.

• Lucintel의 예측에 따르면, 제품 유형별로는 합성 UDCA가 대량 생산이 가능하기 때문에 예측 기간 동안 높은 성장이 예상됩니다.
• 용도별로는 간질환 치료에 대한 수요 증가로 인해 약국이 높은 성장세를 보일 것으로 예측됩니다.
• 지역별로는 헬스케어 투자 증가로 인해 APAC 지역이 예측 기간 동안 가장 높은 성장을 보일 것으로 예측됩니다.

우르소데옥시콜산 API 시장의 새로운 트렌드

간 질환 치료에 대한 수요의 끊임없는 변화, 제약 기술의 성장, 지속 가능한 제조를 향한 움직임은 업계의 구조를 바꾸고 있으며, 우르소데옥시콜산 API 시장도 그 흐름에서 벗어나지 않고 있습니다. 그렇다면 시장에 영향을 미치는 5가지 트렌드를 살펴보자.

• 혁신 부문의 괄목할만한 성장: 우르소데옥시콜산의 기존 용도에 대한 연구 개발의 혁신 타워는 이전보다 더 넓어졌습니다. 예를 들어, 생산자는 NAFLD뿐만 아니라 간섬유증도 간질환 목록에 포함시켰습니다. 이는 우르소데옥시콜산의 새로운 제형 창출, 나아가 새로운 사업 확장을 위한 경쟁을 자극하는 현상입니다. 연구 개발 시스템에 더 많은 통합은 우르소데옥시콜산 원료를 다른 간 질환에 사용되는 것과 차별화하여 환자의 치료 결과를 개선하는 데 도움이 될 것입니다.
• 제조의 지속가능성: 환경 친화적인 제조법을 요구하는 시장이 확대되고 있으며, 우르소데옥시콜산 원료의약품의 제조도 마찬가지입니다. 제조업체는 폐기물 최소화, 물 절약, 이산화탄소 배출량 감소 등 환경 악화에 미치는 영향이 적은 친환경 기술을 채택하고 있습니다. 제약업계에서도 지속 가능한 생산이 주목받고 있습니다. 친환경 제법에 대한 규제 당국의 요구와 소비자의 기대가 높아지면서 우르소데옥시콜산 제조업체도 트렌드에 맞추어 움직일 수밖에 없는 상황입니다.
• 제형의 발전: 서방형 및 서방형 우르소데옥시콜산 제제와 같은 새로운 정교한 제형의 도입은 업계의 새로운 추세를 보여줍니다. 이러한 제제는 환자의 치료 순응도를 높일 뿐만 아니라 치료 효과도 더 높습니다. 간 질환 치료의 개선은 또한 우르소데옥시콜산 원료의약품 생산업체에게 표적화된 약물 전달의 큰 잠재력을 약속하고 있습니다.
• 신흥 지역 수요 증가: 인도, 중국, 동남아시아 등 시장에서 간 질환의 유병률이 증가함에 따라 우르소데옥시콜산 원료의약품에 대한 수요가 증가하고 있습니다. 의료 인프라가 확충되고, 간질환 치료를 찾는 사람들이 늘어나면서 저렴하고 효과적인 치료법에 대한 요구가 높아지고 있습니다. 제조업체들은 이러한 시장 수요 증가에 대응하기 위해 우르소데옥시콜산 원료를 저렴한 가격으로 제조하는 데 중점을 두고 있으며, 이는 시장 성장을 가속하고 있습니다.
• 간질환 치료 관련 우호적 규제: 많은 국가들이 간질환 치료제의 연구개발 및 허가를 지원하기 위해 시장 친화적인 정책을 수립하고 시행하려고 노력하고 있습니다. 각국 정부와 규제 당국은 우르소데옥시콜산과 같은 의약품에 인센티브를 부여하고 신속한 승인을 제공함으로써 전 세계적으로 증가하는 간 질환의 부담에 대응하고 있습니다. 이 현상은 일부 시장에서 우르소데옥시콜산 원약의 빠른 유통을 돕고 제조업체를 돕고 있습니다.

연구개발에 대한 집중, 지속가능성, 정교한 약물 처방, 우르소데옥시콜산 원료의약품의 새로운 시장 견인력, 유리한 정책 설정 등 이러한 새로운 동향은 우르소데옥시콜산 원료의약품 시장을 변화시키고 있으며, 제조업체들에게 새로운 기회와 함께 과제를 제공합니다. 이러한 변화는 보다 지속 가능하고, 혁신적이며, 환자 중심의 참여형 솔루션으로의 성장을 가속할 가능성이 높습니다.

우르소데옥시콜산 API 시장의 최근 동향

우르소데옥시콜산(ursodeoxycholic acid) 원료의약품 시장에는 현재와 미래 전망에 영향을 미치는 주목할 만한 변화가 있습니다. 이러한 변화는 기술 발전, 정책 변화, 우르소데옥시콜산의 다른 잠재적 치료 용도에 대한 연구 관심 증가에 따른 것입니다. 주목할 만한 5가지 변화를 꼽자면 다음과 같습니다.

• 생산 기술의 발전 : 제조 기술의 발전 : 제조 산업에서 더 나은 제조 방법의 채택도 우르소데옥시콜산 API 시장을 촉진하고 있습니다. 연속 생산 및 기타 고도의 정제 방법 등 제조 공정의 자동화 기술 도입으로 고품질의 저비용 우르소데옥시콜산 원료를 생산할 수 있게 되었습니다. 이러한 개발을 통해 생산자들은 국제적인 수요 증가에 대응하면서 세계 품질 기준을 유지할 수 있게 되었습니다.
• 비알코올성 지방간염(NASH)에 대한 관심: 비알코올성 지방간염(NASH) 및 기타 간 질환에 대한 미충족 수요는 공공 및 민간 부문의 R&D 지출 증가로 인해 증가하고 있습니다. NASH, B형 간염 등의 치료에서 우르소데옥시콜산의 가능성을 탐색하는 데 점점 더 많은 관심이 집중되고 있습니다. 연구개발이 진행됨에 따라 원약 수요와 함께 우르소데옥시콜산의 사용 범위도 확대될 것으로 예측됩니다.
• 기존 의약품의 새로운 용도 승인: 기존 의약품의 새로운 용도 승인을 허용하는 규정은 우르소데옥시콜산 기반 제품 시장에서의 진전을 두드러지게 하고 있습니다. 당국은 우르소데옥시콜산을 더 넓은 범위의 간 질환 치료에 사용할 수 있도록 승인하여 치료 범위가 넓어지고 있습니다. 우르소데옥시콜산 제제 시장 개척을 가속화하기 위해 각 업체들은 우르소데옥시콜산 제제 개발에 힘쓰고 있습니다.
• 환경 친화적 생산에 대한 노력: 우르소데옥시콜산 원료의약품 제조업체 중 일부는 환경을 고려하고 규제 당국이 주목하는 가운데, 보다 환경적으로 지속 가능한 방식으로 생산을 시작하는 기업도 늘고 있습니다. 이러한 행동에는 폐기물의 양을 줄이고, 에너지 전략을 보다 효율적인 것으로 바꾸고, 화학 공정에서 유해 물질을 덜 사용하는 것 등이 포함됩니다. 이러한 활동을 통해 우르소데옥시콜산 원액 제조업체는 환경 보호에 기여하고 지속가능성에 관한 다양한 국제 기준을 충족시킬 수 있습니다.
• 협업을 통한 시장 확대: 다른 시장과 마찬가지로 우르소데옥시콜산 원료의약품 사업에서도 제약회사와 R&D 기관과의 전략적 제휴가 점차 중요해지고 있습니다. 이번 제휴를 통해 우르소데옥시콜산의 새로운 제형과 치료용도 창출에 있어 시너지 효과를 강화할 수 있을 것으로 기대됩니다. 동시에, 이러한 제휴는 우르소데옥시콜산 원료의약품의 국제 유통을 개선하여 더 많은 신흥국에서 사용할 수 있도록 하고 있습니다.

강화된 기술, 연구개발 투자 확대, 보조금, 지속가능성 대책 등의 측면이 UCDA의 API 시장에 긍정적인 방향을 제시하고 있습니다. 혁신, 업무 효율화, 새로운 치료 적응증 창출은 이러한 현상을 활용하고 증가하는 세계 수요를 충족시키기 위해 제조업체들이 집중하고 있는 부분입니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 우르소데옥시콜산 API 시장 : 유형별

• 개요
• 유형별 매력 분석
• 합성 UDCA : 동향과 예측(2019년-2031년)
• 추출 UDCA : 동향과 예측(2019년-2031년)

제5장 우르소데옥시콜산 API 시장 : 용도별

• 개요
• 용도별 매력 분석
• 약학 : 동향과 예측(2019년-2031년)
• 건강 제품 : 동향과 예측(2019년-2031년)

제6장 지역 분석

• 개요
• 지역별 우르소데옥시콜산 API 시장

제7장 북미의 우르소데옥시콜산 API 시장

• 개요
• 북미의 우르소데옥시콜산 API 시장, 유형별
• 북미의 우르소데옥시콜산 API 시장, 용도별
• 미국의 우르소데옥시콜산 API 시장
• 멕시코의 우르소데옥시콜산 API 시장
• 캐나다의 우르소데옥시콜산 API 시장

제8장 유럽의 우르소데옥시콜산 API 시장

• 개요
• 유럽의 우르소데옥시콜산 API 시장, 유형별
• 유럽의 우르소데옥시콜산 API 시장, 용도별
• 독일의 우르소데옥시콜산 API 시장
• 프랑스의 우르소데옥시콜산 API 시장
• 스페인의 우르소데옥시콜산 API 시장
• 이탈리아의 우르소데옥시콜산 API 시장
• 영국의 우르소데옥시콜산 API 시장

제9장 아시아태평양의 우르소데옥시콜산 API 시장

• 개요
• 아시아태평양의 우르소데옥시콜산 API 시장, 유형별
• 아시아태평양의 우르소데옥시콜산 API 시장, 용도별
• 일본의 우르소데옥시콜산 API 시장
• 인도의 우르소데옥시콜산 API 시장
• 중국의 우르소데옥시콜산 API 시장
• 한국의 우르소데옥시콜산 API 시장
• 인도네시아의 우르소데옥시콜산 API 시장

제10장 기타 지역의 우르소데옥시콜산 API 시장

• 개요
• 기타 지역의 우르소데옥시콜산 API 시장, 유형별
• 기타 지역의 우르소데옥시콜산 API 시장, 용도별
• 중동의 우르소데옥시콜산 API 시장
• 남미의 우르소데옥시콜산 API 시장
• 아프리카의 우르소데옥시콜산 API 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 교섭력
  • 공급 기업의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형별 성장 기회
  • 용도별 성장 기회
• 우르소데옥시콜산 API 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 합병, 인수, 계약, 제휴 및 합작투자

제13장 밸류체인 주요 기업 개요

• Competitive Analysis
• ICE
• Mitsubishi Tanabe Pharma
• Daewoong Chemical
• PharmaZell
• Zhongshan Bailing
• Dipharma Francis
• Grindeks

제14장 부록

• 도표
• 표 리스트
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• 당사에 대해
• 문의

영문목차

The future of the global ursodeoxycholic acid API market looks promising with opportunities in the pharmacy and health product markets. The global ursodeoxycholic acid API market is expected to grow with a CAGR of 11.2% from 2025 to 2031. The major drivers for this market are the increasing prevalence of liver diseases, the rising adoption of ursodeoxycholic acid for treating gallstones, and the growing healthcare spending.

• Lucintel forecasts that, within the type category, synthetic UDCA is expected to witness higher growth over the forecast period due to its large-scale production.
• Within the application category, pharmacy is expected to witness higher growth due to the increasing demand for liver disease treatments.
• In terms of region, APAC is expected to witness the highest growth over the forecast period due to the rising healthcare investments.

Emerging Trends in the Ursodeoxycholic Acid API Market

The constant changes in the demand for liver disease treatments, the growth of pharmaceutical technology, and the movement toward sustainable manufacturing are shifting how the industry works, and the ursodeoxycholic acid API market is not off the hook either. Given these observations, take a look at five trends affecting the market.

• Alarming Growth in the Innovation Arms: The innovation towers of R&D for the existing application of ursodeoxycholic acid are wider than before. For example, the producers are looking beyond NAFLD and include hepatic fibrosis in the liver disease list. This constitutes a phenomenon that stimulates competition toward the creation of new formulations of ursodeoxycholic acid and hence new business expansions. Further integration into the R&D systems will be beneficial for the differentiation of the ursodeoxycholic acid APIs from those used in other liver disorders and for the enhancement of treatment outcomes for patients.
• Sustainability in Manufacturing: There is a growing market with a demand for eco-friendly practices, and the production of ursodeoxycholic acid APIs is no different. Manufacturers are adopting green technologies that have less of an environmentally degrading effect, including waste minimization, water conservation, and reduction of carbon emissions. Even in the pharmaceutical industry, sustainable production is being given a lot of attention. With regulatory demands and consumer expectations for environmentally friendly practices, ursodeoxycholic acid manufacturers have no option but to move with the trends.
• Advancements in Drug Formulations: The introduction of new sophisticated drug formulations like slow-release and sustained-release ursodeoxycholic acid-based drugs is a mark of the new trend of the industry. Such drug formulations would not only be more effective in enabling patients to comply with treatment but also more effective therapeutically. Improvements in liver disease treatment also provide great potential for targeted drug delivery promises for ursodeoxycholic acid API producers.
• Increased Demand from Emerging Regions: The pace rising prevalence of liver diseases in markets like India, China, and Southeast Asia is boosting the demand for ursodeoxycholic acid APIs. With the improvement in healthcare infrastructure and an increasing number of individuals seeking treatment for liver disorders, the need for affordable and effective therapies is on the rise. Manufacturers are shifting their focus to produce ursodeoxycholic acid APIs at lower prices to meet the rising demand in these markets, thereby propelling the growth of the market.
• Favorable Regulations about Liver Disease Treatment: A number of countries are trying to establish and implement policies that are friendly for the market in the purpose or aid the research, development, and approval of new liver disease treatment options. Governments and regulators have responded to the increase in the global burden of liver diseases by incentivizing and providing fast-track approval for drugs like ursodeoxycholic acid. This phenomenon is assisting in the rapid distribution of ursodeoxycholic acid APIs in several markets, which helps the manufacturers.

These emerging trends, which include R&D focus, sustainability, sophisticated drug formulation, new market drives from ursodeoxycholic acid APIs, and favorable policy setup, are transforming the ursodeoxycholic acid API market by providing new opportunities along with challenges to the manufacturers. The shifts are likely to push growth towards more sustainable, innovative, and patient-centric engagement solutions.

Recent Developments in the Ursodeoxycholic Acid API Market

There are notable changes in the market for Active Pharmaceutical Ingredient of Ursodeoxycholic Acid (ursodeoxycholic acid) that are affecting its present and future landscape. These changes are due to improved technology, changes in policies, and increased focus on research regarding other potential therapeutic uses of ursodeoxycholic acid. Given below are five notable changes:

• Advances in Production Technology: Adoption of better production methods in manufacturing industries is also helping the ursodeoxycholic acid API market. The introduction of automated techniques in production processes, like continuous manufacturing and other advanced methods of purification, has produced high-quality, but low-cost ursodeoxycholic acid APIs. These developments have allowed producers to maintain the growing global quality standards while meeting the increasing international demand.
• Focus on Non-Alcoholic Steatohepatitis (NASH): The increased spending both in public and private sectors on research and development by pharmaceutical companies is fueling the unmet needs of nonalcoholic steatohepatitis (NASH) and other liver diseases. There is an increasing focus on exploring the potential of ursodeoxycholic acid for treating conditions like NASH and hepatitis B. It is anticipated that with the increasing efforts in research and development, the scope of usage for ursodeoxycholic acid will increase along with the demand for its APIs.
• New Approval for Using Existing Drugs: The regulations that allow for the approval of new uses for existing drugs highlight the progress made in the market for ursodeoxycholic acid-based products. The use of ursodeoxycholic acid for the treatment of a wider scope of liver diseases is being granted by the governing authorities, which is broadening its therapeutic scope. With attempts by marketing ursodeoxycholic acid-based products, the companies are trying to comply with them so that they can accelerate the development of new formulations of ursodeoxycholic acid drugs.
• Efforts Towards Even More Environmentally Friendly Production: There is an increasing number of ursodeoxycholic acid API manufacturers that, in light of heightened eco-friendly concern and regulatory attention, have started to produce in a more environmentally sustainable manner. Such actions may involve decreasing the amount of waste, changing energy strategies to more efficient ones, and using less hazardous substances for the chemical processes. These activities will allow the manufacturers of the ursodeoxycholic acid API to contribute to the care of the environment and help them meet various international standards of sustainability.
• Market Expansion through Collaborations: As it is in other markets, the strategic partnering of pharmaceutical firms with research and development institutions has been progressively more important in the ursodeoxycholic acid API business. Such collaborations facilitate the consolidation of synergies in the creation of new formulations and therapeutic uses of ursodeoxycholic acid. At the same time, these collaborations are improving the international distribution of ursodeoxycholic acid APIs to make them available in more developing countries.

Aspects such as enhanced technologies, growing investments into R&D, grants, and sustainability measures are UCDA API market forces looking in the forward direction. Innovation, operating efficiency, and creating new therapeutic indications are the focuses of the manufacturers to take advantage of the phenomena and satisfy the increasing global needs.

Strategic Growth Opportunities in the Ursodeoxycholic Acid API Market

Several strategic growth prospects exist in the application of the ursodeoxycholic acid API, which is simultaneously and operationally utilized in different spheres. The same is augmented due to the increased need for liver disease treatments, technological innovations, and growth of other pharmaceutical markets. These include but are not limited to these five opportunities:

• Increasing Application in Liver Disease Conditions: With the increase in the number of people suffering from liver diseases, there is a great potential for improvement of ursodeoxycholic acid APIs in PBC, fatty liver disease, and cirrhosis. As the focus on the management of liver diseases increases, there is a corresponding increase in the need for drugs based on ursodeoxycholic acid. Hence, this factor largely increases the growth of UDC APIs.
• Concentrating on Emerging Markets: Ursodeoxycholic acid API producers stand to gain enormously from newly industrialized regions in Asia and Africa. The demand for affordable treatment options is estimated to rise as the healthcare infrastructure improves and there is an increase in the awareness of liver diseases. To serve these emerging markets, manufacturers are looking to provide cost-effective ursodeoxycholic acid APIs.
• Tackling Non-Alcoholic Fatty Liver Disease (NAFLD): The rising obesity rates and the growing occurrence of NAFLD is a huge opportunity for the growth of ursodeoxycholic acid APIs. There are ongoing studies that aim to assess the efficacy of ursodeoxycholic acid in the treatment of NAFLD, and with the advancement of clinical trials, this could possibly create a new market segment for drugs based on ursodeoxycholic acid.
• Innovative Systems of Drug Delivery: The development of new systems of drug delivery, particularly sustained release and oral dosage forms, provides a unique opportunity for growth with ursodeoxycholic acid APIs. Increased patient adherence coupled with improved therapeutic efficacy from these systems will undoubtedly increase the use of ursodeoxycholic acid-based treatments.
• Market Expansion by Collaboration and Partnerships: The merging of manufacturers, research centers, and healthcare facilities allows for the strategic marketing of the ursodeoxycholic acid API on an international scale. Involving other stakeholders in the pharmaceutical supply chain facilitates manufacturers in product development, distribution, and access to international markets.

These partnerships along with innovations in drug delivery, treatment expansion in emerging markets, and focus on NAFLD, offer the strategic growth opportunities that are likely to foster the future of the ursodeoxycholic acid API market. Those manufacturers who pursue them will reap the benefits of a well-established position in the long term.

Ursodeoxycholic Acid API Market Driver and Challenges

Like many other markets, the ursodeoxycholic acid API market is being driven and challenged by many factors which influence its growth. Also featured are new technological developments, increasing treatment needs for liver diseases, and the many facets of liver disease regulatory scope. Five drivers and three different challenges are provided below.

The factors responsible for driving the ursodeoxycholic acid API market include:

1. Rising Prevalence of Liver Diseases: Cirrhosis, NAFLD, PBC, and other liver disorders and their increasing prevalence globally is one of the key drivers of the ursodeoxycholic acid API market. More people being diagnosed with liver disorders leads to an increased need for medical attention, which results in higher consumption of drugs based on ursodeoxycholic acid. This helps in the growth of the market.

2. Advancements in Pharmaceutical Manufacturing: Continuous manufacturing, streamlined purification processes, and other advanced manufacturing technologies are creating better and less expensive ursodeoxycholic acid APIs. Increased efficiency and scalability of production positively impact the market.

3. Support from the Government for Liver Disease Treatments: New treatments for liver disease, such as those which utilize ursodeoxycholic acid, are getting assistance from governments and regulatory bodies across the world. The growth of the ursodeoxycholic acid API market is driven by the quick approval processes and subsidies for liver disease therapies.

4. Greater Focus on Healthcare: Demand for medicines that use ursodeoxycholic acid is growing due to increased awareness of the treatment and prevention of liver disease. As people become more educated on maintaining their liver health, the willingness to seek medical attention rises, which benefits the ursodeoxycholic acid API market.

5. More Funding in R&D Activity: There is a large investment from within the pharmaceutical industry in research and development to find new therapeutic uses of ursodeoxycholic acid. The market is being expanded by this investment through the introduction of new indications and improvement of the effectiveness of the ursodeoxycholic acid-based treatments.

Challenges in the ursodeoxycholic acid API market are:

1. Barriers in Regulation: The multi-step and tedious regulatory approval process for new drugs, including those that are ursodeoxycholic acid-based, can be difficult for manufacturers to navigate. Regulatory hurdles tend to delay the introduction of new products into the market, which restricts growth.

2. Price Sensitivity in Emerging Markets: Growing price sensitivity in emerging markets poses a problem for ursodeoxycholic acid API manufacturers. The limited spending of healthcare systems in these parts of the world could make it difficult for manufacturers to profitably provide affordable ursodeoxycholic acid-based drugs.

3. Patent Expirations and Generic Competition: Generic manufacturers are increasingly competing with original developers due to the expiration of patents for ursodeoxycholic acid-based drugs. While this competition drives the price of ursodeoxycholic acid-based treatments down, it also makes it harder for original developers to retain their market share.

The market for ursodeoxycholic acid APIs is subjected to the increase in liver diseases, new technologies, favorable regulations, growth in healthcare awareness, and R&D spending, but also to the continuous regulatory burden in the United States, sensitivity to pricing, and competition from generic drugs. Manufacturers have to find ways to deal with these issues if market growth and other challenges are to be met successfully.

List of Ursodeoxycholic Acid API Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, ursodeoxycholic acid API companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ursodeoxycholic acid API companies profiled in this report include:

• ICE
• Mitsubishi Tanabe Pharma
• Daewoong Chemical
• PharmaZell
• Zhongshan Bailing
• Dipharma Francis
• Grindeks

Ursodeoxycholic Acid API Market by Segment

The study includes a forecast for the global ursodeoxycholic acid API market by type, application, and region.

Ursodeoxycholic Acid API Market by Type [Value from 2019 to 2031]:

• Synthetic UDCA
• Extraction UDCA

Ursodeoxycholic Acid API Market by Application [Value from 2019 to 2031]:

• Pharmacy
• Health Products

Ursodeoxycholic Acid API Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Ursodeoxycholic Acid API Market

This ursodeoxycholic acid API market is influenced by ongoing innovation in the pharmaceutical sector, growth in the liver disease treatment market, and increasing knowledge about the advantages of ursodeoxycholic acid. Some areas like the US, China, Germany, India, and Japan are showing marked changes in the ursodeoxycholic acid market. Improvement in manufacturing procedures, approved regulations, and growing numbers of clinical studies are factors contributing to growth in the market. A summary of the recent progress in the ursodeoxycholic acid API market of these countries is outlined below.

• United States: The United States is showing positive growth trends because of the growing number of liver diseases such as primary biliary cirrhosis (PBC). The demand for these drugs is increasing with the approval of ursodeoxycholic acid-based therapies for different liver disorders. Now, there is also an increasing emphasis on developing more sophisticated UCDA formulations. The quality and price of the APIs are also being enhanced by the manufacturers, resulting in better penetration of ursodeoxycholic acid-based therapies in the market. In addition, clinical research and trials are actively conducted in the area with encouraging results showing potential for treating other liver conditions, which is fueling market growth.
• China: Known for its unrivaled production capabilities and low-cost manufacturing, China has emerged as a world leader in the ursodeoxycholic acid API market. There is growing demand for ursodeoxycholic acid in China due to the improving healthcare system and increasing number of patients seeking treatment for liver diseases. The support by the Chinese government's policies for the pharmaceutical sector also greatly improves access to quality ursodeoxycholic acid APIs. Additionally, China's position in the ursodeoxycholic acid API market is being strengthened by the increasing number of clinical trials and research activities in the region, along with the adoption of new advanced manufacturing technologies.
• Germany: In Germany, the demand for ursodeoxycholic acid APIs is driven by advancements in the pharmaceutical sector. There is also a growing number of patients being diagnosed with liver diseases. The robust healthcare system in Germany, along with a high level of new drug utilization, drives the use of ursodeoxycholic acid medications. The German government also facilitates treatment innovation for liver diseases within the country. There is also an increase in R&D activities in Germany aimed at optimizing the ursodeoxycholic acid formulations and developing new therapeutic uses, and this is also contributing to market growth.
• India: The increasing demand for ursodeoxycholic acid APIs in India stems from both the growth of the healthcare sector and the rising cases of liver disorders in the country. There is ursodeoxycholic acid API production in India offered at competitive prices and of high quality to meet the global market demand. The Indian pharmaceutical industry is also funding R&D for enhanced formulations of ursodeoxycholic acid and other liver disease therapeutics. Growth in population awareness and the country's improved healthcare accessibility are further expected to drive the rise in ursodeoxycholic acid API sales in India.
• Japan: The ursodeoxycholic acid API market in Japan is continuously growing, which is largely attributed to the aging population and the high prevalence of liver diseases in the country. There is wide usage of ursodeoxycholic acid and cholic acid in Japan for liver disorder treatment, and the demand for better formulations is on the rise. Japanese pharmaceutical manufacturers are dedicated to using high-grade manufacturing equipment to produce superior quality ursodeoxycholic acid APIs in order to meet the stringent regulatory requirements in Japan. Moreover, the increase of Japan's investment into health R&D will most likely increase the use of ursodeoxycholic acid APIs, especially for chronic liver diseases.

Features of the Global Ursodeoxycholic Acid API Market

• Market Size Estimates: Ursodeoxycholic acid API market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Ursodeoxycholic acid API market size by type, application, and region in terms of value ($B).
• Regional Analysis: Ursodeoxycholic acid API market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the ursodeoxycholic acid API market.
• Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the ursodeoxycholic acid API market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the ursodeoxycholic acid API market by type (synthetic UDCA and extraction UDCA), application (pharmacy and health products), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Ursodeoxycholic Acid API Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Synthetic UDCA: Trends and Forecast (2019-2031)
• 4.4 Extraction UDCA: Trends and Forecast (2019-2031)

5. Global Ursodeoxycholic Acid API Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Pharmacy: Trends and Forecast (2019-2031)
• 5.4 Health Products: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Ursodeoxycholic Acid API Market by Region

7. North American Ursodeoxycholic Acid API Market

• 7.1 Overview
• 7.2 North American Ursodeoxycholic Acid API Market by Type
• 7.3 North American Ursodeoxycholic Acid API Market by Application
• 7.4 United States Ursodeoxycholic Acid API Market
• 7.5 Mexican Ursodeoxycholic Acid API Market
• 7.6 Canadian Ursodeoxycholic Acid API Market

8. European Ursodeoxycholic Acid API Market

• 8.1 Overview
• 8.2 European Ursodeoxycholic Acid API Market by Type
• 8.3 European Ursodeoxycholic Acid API Market by Application
• 8.4 German Ursodeoxycholic Acid API Market
• 8.5 French Ursodeoxycholic Acid API Market
• 8.6 Spanish Ursodeoxycholic Acid API Market
• 8.7 Italian Ursodeoxycholic Acid API Market
• 8.8 United Kingdom Ursodeoxycholic Acid API Market

9. APAC Ursodeoxycholic Acid API Market

• 9.1 Overview
• 9.2 APAC Ursodeoxycholic Acid API Market by Type
• 9.3 APAC Ursodeoxycholic Acid API Market by Application
• 9.4 Japanese Ursodeoxycholic Acid API Market
• 9.5 Indian Ursodeoxycholic Acid API Market
• 9.6 Chinese Ursodeoxycholic Acid API Market
• 9.7 South Korean Ursodeoxycholic Acid API Market
• 9.8 Indonesian Ursodeoxycholic Acid API Market

10. ROW Ursodeoxycholic Acid API Market

• 10.1 Overview
• 10.2 ROW Ursodeoxycholic Acid API Market by Type
• 10.3 ROW Ursodeoxycholic Acid API Market by Application
• 10.4 Middle Eastern Ursodeoxycholic Acid API Market
• 10.5 South American Ursodeoxycholic Acid API Market
• 10.6 African Ursodeoxycholic Acid API Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Ursodeoxycholic Acid API Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 ICE
  • Company Overview
  • Ursodeoxycholic Acid API Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Mitsubishi Tanabe Pharma
  • Company Overview
  • Ursodeoxycholic Acid API Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Daewoong Chemical
  • Company Overview
  • Ursodeoxycholic Acid API Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 PharmaZell
  • Company Overview
  • Ursodeoxycholic Acid API Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Zhongshan Bailing
  • Company Overview
  • Ursodeoxycholic Acid API Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Dipharma Francis
  • Company Overview
  • Ursodeoxycholic Acid API Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Grindeks
  • Company Overview
  • Ursodeoxycholic Acid API Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us